Hosted on MSN2mon
Eyenovia Stock Tumbles on Termination of Phase III Myopia Studydetermined that the phase III CHAPERONE study of MicroPine was unlikely to meet its primary endpoint of less than 0.5 diopter progression in visual acuity over three years. The DRC evaluated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback